Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016225 | 0.91 | LMNA (0.40) | LMNACYP2C19HIF1A | |
| SCHEMBL3030371 | 0.89 | LMNA (0.49) | LMNACYP2C19HIF1A | |
| SCHEMBL10044848 | 0.87 | LMNA (0.61) | LMNACYP2C19HIF1A | |
| SCHEMBL13327918 | 0.87 | LMNA (0.47) | LMNACYP2C19HIF1A | |
| SCHEMBL10044845 | 0.87 | LMNA (0.55) | LMNACYP2C19HIF1A | |
| SCHEMBL4154741 | 0.86 | LMNA (0.53) | LMNACYP2C19HIF1A | |
| SCHEMBL13327930 | 0.86 | LMNA (0.46) | LMNACYP2C19HIF1A | |
| SCHEMBL3026646 | 0.85 | LMNA (0.36) | LMNA | |
| SCHEMBL709410 | 0.84 | LMNA (0.33) | LMNA | |
| SCHEMBL3020429 | 0.83 | LMNA (0.46) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200971-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2013-04-24 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| EP-2200655-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-07-18 | — | — | EP | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20100189656-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-07-29 | — | — | US | disclosed |
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| US-20090098059-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-04-16 | — | — | US | disclosed |
| EP-2021317-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009005364-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005364-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-01-08 | — | — | WO | disclosed |
| WO-2007133090-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098059-A1 | CONTRAST AGENTS | IPO4, IPO11, IPO8 | LMNA 1824/4885CYP2C19 4562/4885HIF1A 402/4885 |
| US-20100189656-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 1835/4885CYP2C19 4234/4885HIF1A 1213/4885 |
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | LMNA 2025/4885CYP2C19 2823/4885HIF1A 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.